Arbutus Biopharma buys back 46,000,000 shares for US$ 230 million in Dutch auction tender offer

By Public Technologies
  • Arbutus completed a modified Dutch auction tender offer, repurchasing 46,000,000 common shares for cancellation at US$ 5.00 each.
  • Total buyback value reached US$ 230 million, representing about 23% of shares outstanding as of Sept. 29, 2026.
  • Offer was oversubscribed; eligible tenders at or below US$ 5.00 were prorated to about 55.6%, excluding odd lots.
  • Roivant Sciences tendered in the proportionate pool, maintaining about 19.5% ownership following completion.
  • Shares not purchased will be returned; payment and settlement expected around Oct. 5, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010730PRIMZONEFULLFEED9837627) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.